Ocular Pain - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ocular Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Ocular Pain - Pipeline Review, H1 2016', provides an overview of the Ocular Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
- The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain - Overview 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
InSite Vision Incorporated 14
Kala Pharmaceuticals, Inc. 15
Ocular Therapeutix, Inc. 16
Reata Pharmaceuticals, Inc. 17
Sylentis S.A.U. 18
Valeant Pharmaceuticals International, Inc. 19
Ocular Pain - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(bromfenac sodium + dexamethasone acetate) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexamethasone acetate SR - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
difluprednate XR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISV-303 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
loteprednol etabonate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
loteprednol etabonate next generation - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NT-71 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NT-72 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omaveloxolone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RX-10045 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SYL-1001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Ocular Pain - Recent Pipeline Updates 48
Ocular Pain - Dormant Projects 61
Ocular Pain - Product Development Milestones 62
Featured News & Press Releases 62
Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 62
Jan 11, 2016: Ocular Therapeutix Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer 62
Dec 09, 2015: Ocular Therapeutix Announces FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain 63
Oct 14, 2015: Ocular Therapeutix Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain 64
Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 64
Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 65
May 15, 2015: Ocular Therapeutix Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication 65
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 67
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 67
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for Ocular Pain, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2016 14
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 15
Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H1 2016 16
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 17
Ocular Pain - Pipeline by Sylentis S.A.U., H1 2016 18
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Assessment by Combination Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2016 48
Ocular Pain - Dormant Projects, H1 2016 61